The HGF-Met signaling axis: Emerging themes and targets of inhibition

Current Protein and Peptide Science

Volumn 12, Issue 1, 2011, Pages 12-22

  Steffan, Joshua J ^a   Coleman, David T ^a   Cardelli, James A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

C Met; EGCG; HGF; Invasion; Lysosome trafficking; Polyphenols; Signal transduction

Indexed keywords

CLATHRIN; CRIZOTINIB; ENDOPHILIN; EPICATECHIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; FORETINIB; GEFITINIB; JNJ 38877605; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OA5D5; PF 04217903; PHOSPHOPROTEIN PHOSPHATASE 2A; PLANT MEDICINAL PRODUCT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPHENOL; POLYPHENOL DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE; RECEPTOR; RESVERATROL; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 184;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATTENUATION; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL TRIAL (TOPIC); DIMERIZATION; DRUG BINDING; DRUG INHIBITION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXOCYTOSIS; FIBROBLAST; GENE OVEREXPRESSION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; METASTASIS; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PANCREAS TUMOR; PLANT; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA CELL; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR MICROENVIRONMENT; UBIQUITINATION;

EID: 79958082872     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920311795659425     Document Type: Review

References (141)

1. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4, 915-925.
2. Gu, H.; Neel, B.G. The 'Gab' in signal transduction. Trends Cell Biol., 2003, 13, 122-130.
3. Rosário, M.; Birchmeier, W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol., 2003, 13, 328-335.
4. Schaeper, U.; Gehring, N.H.; Fuchs, K.P.; Sachs, M.; Kempkes, B.; Birchmeier, W. Coupling of Gab1 to C-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol., 2000, 149, 1419-1432.
5. Gao, C.; Vande Woude, G.F. HGF/SF-Met signaling in tumor progression. Cell Res., 2005, 15, 49-51.
6. Tulasne, D.; Foveau, B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ., 2007, 15, 427-434.
7. Benvenuti, S.; Comoglio, P.M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol., 2007, 213, 316-325.
8. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2, 442-454.
9. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
10. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature, 2001, 410, 37-40.
11. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26, 3279-3290.
12. Bean, J.; Brennan, C.; Shih, J.Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C.J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.F.; Yang, P.C.; Miller, V.; Ladanyi, M.; Yang, C.H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA, 2007, 104, 20932-20937.
13. Cheng, T.L.; Chang, M.Y.; Huang, S.Y.; Sheu, C.C.; Kao, E.L.; Cheng, Y.J.; Chong, I.W. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest, 2005, 128, 1453-1460.
14. Gillies, R.J.; Gatenby, R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Met. Rev., 2007, 26, 311-317.
15. Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8, 56-61.
16. Hsu, P.; Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell, 2008, 134, 703-707.
17. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899.
18. Yeluri, S.; Madhok, B.; Prasad, K.; Quirke, P.; Jayne, D. Cancer's craving for sugar: an opportunity for clinical exploitation. J. Can. Res. Clin. Onc., 2009, 135, 867-877.
19. Vavere, A.L.; Biddlecombe, G.B.; Spees, W.M.; Garbow, J.R.; Wijesinghe, D.; Andreev, O.A.; Engelman, D.M.; Reshetnyak, Y.K.; Lewis, J.S. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res., 2009, 69, 4510-4516.
20. Garber, K. Energy boost: The Warburg effect returns in a new theory of cancer. J. Natl. Cancer Inst., 2004, 96, 1805-1806.
21. Samudio, I.; Fiegl, M.; Andreeff, M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res., 2009, 69, 2163-2166.
22. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell, 2008, 13, 472-482.
23. Yamagata, M.; Hasuda, K.; Stamato, T.; Tannock, I.F. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer, 1998, 77, 1726-1731.
24. Tannock, I.F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res., 1989, 49, 4373-4384.
25. Svastova, E.; Hulikova, A.; Rafajova, M.; Zat'ovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C.T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett., 2004, 577, 439-445.
26. Kaplan, O.; Firon, M.; Vivi, A.; Navon, G.; Tsarfaty, I. HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia, 2000, 2, 365-377.
27. + exchangers. J. Cell Sci., 2010, 123, 1151-1159.
28. Park, M.; Dean, M.; Kaul, K.; Braun, M.J.; Gonda, M.A.; Vande Woude, G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA, 1987, 84, 6379-6383.
29. Mak, H.H.L.; Peschard, P.; Lin, T.; Naujokas, M.A.; Zuo, D.; Park, M. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene, 2007, 26, 7213-7221.
30. Schelter, F.; Kobuch, J.; Moss, M.L.; Becherer, J.D.; Comoglio, P.M.; Boccaccio, C.; Kruger, A. A disintegrin and metalloprotein ase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem., 2010, 285, 26335-26340.
31. Nath, D.; Williamson, N.J.; Jarvis, R.; Murphy, G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci., 2001, 114, 1213-1220.
32. Tulasne, D.; Deheuninck, J.; Lourenco, F.C.; Lamballe, F.; Ji, Z.; Leroy, C.; Puchois, E.; Moumen, A.; Maina, F.; Mehlen, P.; Fafeur, V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol. Cell. Biol., 2004, 24, 10328-10339.
33. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361.
34. Boccaccio, C.; Comoglio, P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer, 2006, 6, 637-645.
35. Gambarotta, G.; Pistoi, S.; Giordano, S.; Comoglio, P.; Santoro, C. Structure and inducible regulation of the human MET promoter. J. Biol. Chem., 1994, 269, 12852-12857.
36. Morozov, V.M.; Massoll, N.A.; Vladimirova, O.V.; Maul, G.G.; Ishov, A.M. Regulation of c-met expression by transcription repressor Daxx. Oncogene, 2008, 27, 2177-2186.
37. Hashigasako, A.; Machide, M.; Nakamura, T.; Matsumoto, K.; Nakamura, T. Bi-directional regulation of Ser-985 phosphorylation of c-Met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem., 2004, 279, 26445-26452.
38. Gandino, L.; Longati, P.; Medico, E.; Prat, M.; Comoglio, P.M. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J. Biol. Chem., 1994, 269, 1815-1820.
39. Hammond, D.E.; Urbe, S.; Vande Woude, G.F.; Clague, M.J. Down-regualtion of MET, the receptor for hepatocyte growth factor. Oncogene, 2001, 20, 2761-2770.
40. Mosesson, Y.; Mills, G.B.; Yarden, Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer, 2008, 8, 835-850.
41. Peschard, P.; Fournier, T.M.; Lamorte, L.; Naujokas, M.A.; Band, H.; Langdon, W.Y.; Park, M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell, 2001, 8, 995-1004.
42. Petrelli, A.; Gilestro, G.F.; Lanzardo, S.; Comoglio, P.M.; Migone, N.; Giordano, S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature, 2002, 416, 187-190.
43. Li, N.; Lorinczi, M.; Ireton, K.; Elferink, L.A. Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase. J. Biol. Chem., 2007, 282, 16764-16775.
44. Hammond, D.E.; Carter, S.; McCullough, J.; Urbe, S.; Vande Woude, G.F.; Clague, M.J. Endosomal dynamics of Met determine signaling output. Mol. Biol. Cell, 2003, 14, 1346-1354.
45. Raiborg, C.; Rusten, T.E.; Stenmark, H. Protein sorting into multivesicular endosomes. Curr. Opin. Cell Biol., 2003, 15, 446-455.
46. Bonifacino, J.S.; Rojas, R. Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol., 2006, 7, 568-579.
47. Jeffers, M.; Taylor, G.A.; Weidner, K.M.; Omura, S.; Vande Woude, G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol., 1997, 17, 799-808.
48. Kermorgant, S.; Zicha, D.; Parker, P.J. PKC controls HGFdependent c-Met traffic, signalling and cell migration. EMBO J., 2004, 23, 3721-3734.
49. Kermorgant, S.; Zicha, D.; Parker, P J. Protein Kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J. Biol. Chem., 2003, 278, 28921-28929.
50. Carpenter, G. The EGF receptor: a nexus for trafficking and signaling. Bioessays, 2000, 22, 697-707.
51. Niendorf, S.; Oksche, A.; Kisser, A.; Lohler, J.; Prinz, M.; Schorle, H.; Feller, S.; Lewitzky, M.; Horak, I.; Knobeloch, K.-P. Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol. Cell. Biol., 2007, 27, 5029-5039.
52. Shattuck, D.L.; Miller, J.K.; Laederich, M.; Funes, M.; Petersen, H.; Carraway, K.L., III; Sweeney, C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol. Cell. Biol., 2007, 27, 1934-1946.
53. Murphy, J.E.; Padilla, B.E.; Hasdemir, B.; Cottrell, G.S.; Bunnett, N.W. Endosomes: A legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA, 2009, 106, 17615-17622.
54. Sadowski, L.; Pilecka, I.; Miaczynska, M. Signaling from endosomes: Location makes a difference. Exp. Cell Res., 2009, 315, 1601-1609.
55. Kermorgant, S.; Parker, P.J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol., 2008, 182, 855-863.
56. Witz, I.P. Yin-Yang activities and vicious cycles in the tumor microenvironment. Cancer Res., 2008, 68, 9-13.
57. Fokas, E.; Engenhart-Cabillic, R.; Daniilidis, K.; Rose, F.; An, H.-X. Metastasis: the seed and soil theory gains identity. Cancer Met. Rev., 2007, 26, 705-715.
58. Kaplan, R.N.; Rafii, S.; Lyden, D. Preparing the "Soil": The premetastatic niche. Cancer Res., 2006, 66, 11089-11093.
59. Albini, A. Tumor microenvironment, a dangerous society leading to cancer metastasis. From mechanisms to therapy and prevention. Cancer Met. Rev., 2008, 27, 3-4.
60. Chung, L.W.K.; Baseman, A.; Assikis, V.; Zhau, H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol., 2005, 173, 10-20.
61. Galon, J.; Fridman, W.-H.; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res., 2007, 67, 1883-1886.
62. Qian, C.-N.; Berghuis, B.; Tsarfaty, G.; Bruch, M.; Kort, E.J.; Ditlev, J.; Tsarfaty, I.; Hudson, E.; Jackson, D.G.; Petillo, D.; Chen, J.; Resau, J.H.; Teh, B.T. Preparing the "Soil": The primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res., 2006, 66, 10365-10376.
63. Noonan, D.; De Lerma Barbaro, A.; Vannini, N.; Mortara, L.; Albini, A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Met. Rev., 2008, 27, 31-40.
64. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008, 27, 5904-5912.
65. Albini, A.; Sporn, M.B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer, 2007, 7, 139-147.
66. Gatenby, R.A.; Gawlinski, E.T.; Gmitro, A.F.; Kaylor, B.; Gillies, R.J. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res., 2006, 66, 5216-5223.
67. Joyce, J.A.; Pollard, J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 2009, 9, 239-252.
68. Denko, N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer, 2008, 8, 705-713.
69. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer, 2006, 119, 477-483.
70. Xouri, G.; Christian, S. Origin and function of tumor stroma fibroblasts. Semin. Cell Dev. Biol., 2010, 21, 40-46.
71. Xing, F.; Saidou, J.; Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci., 2010, 15, 166-179.
72. Alberti, C. Prostate cancer progression and surrounding microenvironment. Int. J. Biol. Markers, 2006, 21, 88-95.
73. Anderson, A.R.A.; Hassanein, M.; Branch, K.M.; Lu, J.; Lobdell, N.A.; Maier, J.; Basanta, D.; Weidow, B.; Narasanna, A.; Arteaga, C.L.; Reynolds, A.B.; Quaranta, V.; Estrada, L.; Weaver, A.M. Microenvironmental independence associated with tumor progression. Cancer Res., 2009, 69, 8797-8806.
74. Bodenstine, T.; Welch, D.R. Metastasis suppressors and the tumor microenvironment. Cancer Microenviron., 2008, 1, 1-11.
75. Bidard, F.o.-C. m.; Pierga, J.-Y.; Vincent-Salomon, A.; Poupon, M.-F. A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Met. Rev., 2008, 27, 5-10.
76. Pani, G.; Galeotti, T.; Chiarugi, P. Metastasis: cancer cell's escape from oxidative stress. Cancer Met. Rev., 2010, 29, 351-378.
77. Wels, J.; Kaplan, R.N.; Rafii, S.; Lyden, D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev., 2008, 22, 559-574.
78. Turke, A.B.; Zejnullahu, K.; Wu, Y.-L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N.I.; Murphy, C.; Akhavanfard, S.; Yeap, B.Y.; Xiao, Y.; Capelletti, M.; Iafrate, A.J.; Lee, C.; Christensen, J.G.; Engelman, J.A.; Jänne, P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010, 17, 77-88.
79. Surowiak, P.; Suchocki, S.; Gyorffy, B.; Gansukh, T.; Wojnar, A.; Maciejczyk, A.; Pudelko, M.; Zabel, M. Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers. Folia Histochem. Cytobiol., 2006, 44, 111-116.
80. Tsujino, T.; Seshimo, I.; Yamamoto, H.; Ngan, C.Y.; Ezumi, K.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; Matsuura, N.; Monden, M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res., 2007, 13, 2082-2090.
81. Tomas, D.; Ulamec, M.; Hudolin, T.; Bulimbasic, S.; Belicza, M.; Kruslin, B. Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis., 2006, 9, 414-419.
82. Tokunou, M.; Niki, T.; Eguchi, K.; Iba, S.; Tsuda, H.; Yamada, T.; Matsuno, Y.; Kondo, H.; Saitoh, Y.; Imamura, H.; Hirohashi, S. c-MET Expression in Myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma. Am. J. Pathol., 2001, 158, 1451-1463.
83. Mizuno, S.; Matsumoto, K.; Li, M.-Y.; Nakamura, T. HGF reduces advancing lung fibrosis in mice: a potential role for MMPdependent myofibroblast apoptosis. FASEB J., 2005, 19, 580-582.
84. Comoglio, P.M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov, 2008, 7, 504-516.
85. Eder, J.P.; Vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res., 2009, 15, 2207-2214.
86. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signalling pathway in cancer. Eur. J. Cancer, 2010, 46, 1260-1270.
87. Matsumoto, K.; Nakamura, T.; Sakai, K.; Nakamura, T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics, 2008, 8, 3360-3370.
88. Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73.
89. Burgess, T.L.; Sun, J.; Meyer, S.; Tsuruda, T.S.; Sun, J.; Elliott, G.; Chen, Q.; Haniu, M.; Barron, W.F.; Juan, T.; Zhang, K.; Coxon, A.; Kendall, R.L. Biochemical characterization of AMG 102: A neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol. Cancer Ther., 2010, 9, 400-409.
90. Jun, H.T.; Sun, J.; Rex, K.; Radinsky, R.; Kendall, R.; Coxon, A.; Burgess, T.L. AMG 102, a fully human anti-hepatocyte growth factor/ scatter factor neutralizing antibody, enhances the efficacy of Temozolomide or Docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res., 2007, 13, 6735-6742.
91. Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R.A.D.; Kasman, I.; Mai, E.; Young, J.; Zha, J.; Zhang, Z.; Ross, S.; Schwall, R.; Colbern, G.; Merchant, M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res., 2008, 68, 4360-4368.
92. Sattler, M.; Salgia, R. The MET axis as a therapeutic target. Update Cancer Ther., 2009, 3, 109-118.
93. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316, 1039-1043.
94. Bigelow, R.L.H.; Cardelli, J.A. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene, 2006, 25, 1922-1930.
95. Milligan, S.A.; Burke, P.; Coleman, D.T.; Bigelow, R.L.; Steffan, J.J.; Carroll, J.L.; Williams, B.J.; Cardelli, J.A. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res., 2009, 15, 4885-4894.
96. Duhon, D.; Bigelow, R.L.H.; Coleman, D.T.; Steffan, J.J.; Yu, C.; Langston, W.; Kevil, C.G.; Cardelli, J.A. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol. Carcinog., 2010, 49, 739-749.
97. Lim, Y.C.; Park, H.Y.; Hwang, H.S.; Kang, S.U.; Pyun, J.H.; Lee, M.H.; Choi, E.C.; Kim, C.-H. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett., 2008, 271, 140-152.
98. Larsen, C.A.; Dashwood, R.H. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: Minor role of hydrogen peroxide. Biochem. Biophys. Res. Commun., 2009, 389, 527-530.
99. Adachi, S.; Nagao, T.; Ingolfsson, H.I.; Maxfield, F.R.; Andersen, O.S.; Kopelovich, L.; Weinstein, I.B. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res., 2007, 67, 6493-6501.
100. De Ledinghen, V.; Monvoisin, A.; Neaud, V.; Krisa, S.; Payrastre, B.; Bedin, C.; Desmouliere, A.; Bioulac-Sage, P.; Rosenbaum, J. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int. J. Oncol., 2001, 19, 83-88.
101. Tanimura, S.; Kadomoto, R.; Tanaka, T.; Zhang, Y.-J.; Kouno, I.; Kohno, M. Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochem. Biophys. Res. Commun., 2005, 330, 1306-1313.
102. Uddin, S.; Hussain, A.R.; Ahmed, M.; Bu, R.; Ahmed, S.O.; Ajarim, D.; Al-Dayel, F.; Bavi, P.; Al-Kuraya, K.S. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol. Cancer Ther., 2010, 9, 1244-1255.
103. Coleman, D.T.; Bigelow, R.L.H.; Cardelli, J.A. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol. Cancer Ther., 2009, 8, 214-224.
104. Lee, W.-J.; Wu, L.-F.; Chen, W.-K.; Wang, C.-J.; Tseng, T.-H. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem. Biol. Interact., 2006, 160, 123-133.
105. Mishra, P.J.; Mishra, P.J.; Humeniuk, R.; Medina, D.J.; Alexe, G.; Mesirov, J.P.; Ganesan, S.; Glod, J.W.; Banerjee, D. Carcinomaassociated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res., 2008, 68, 4331-4339.
106. McLarty, J.; Bigelow, R.L.H.; Smith, M.; Elmajian, D.; Ankem, M.; Cardelli, J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res., 2009, 2, 673-682.
107. Hung, C.-F.; Huang, T.-F.; Chiang, H.-S.; Wu, W.-B. (-)-Epigallocatechin-3-gallate, a polyphenolic compound from green tea, inhibits fibroblast adhesion and migration through multiple mechanisms. J. Cell. Biochem., 2005, 96, 183-197.
108. Peairs, A.; Dai, R.; Gan, L.; Shimp, S.; Rylander, M.N.; Li, L.; Reilly, C.M. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol. Immunol., 2010, 7, 123-132.
109. Ahmed, S.; Marotte, H.; Kwan, K.; Ruth, J.H.; Campbell, P.L.; Rabquer, B.J.; Pakozdi, A.; Koch, A.E. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. USA, 2008, 105, 14692-14697.
110. Huang, G.-S.; Tseng, C.-Y.; Lee, C.-H.; Su, S.-L.; Lee, H.-S. Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2, PGE2, and IL-8 expression induced by IL-1b in human synovial fibroblasts. Rheum. Int., 2010, 30, 1197-1203.
111. + exchangers and RhoA regulate acidic extracellular pHinduced lysosome trafficking in prostate cancer cells. Traffic, 2009, 10, 737-753.
112. Steffan, J.J.; Cardelli, J.A. Thiazolidinediones induce Rab7-RILPMAPK-dependent juxtanuclear lysosome aggregation and reduce tumor cell invasion. Traffic, 2010, 11, 274-286.
113. Dittman, J.; Ryan, T.A. Molecular circuitry of endocytosis at nerve terminals. Annu. Rev. Cell Dev. Biol., 2009, 25, 133-160.
114. Cremona, O.; Collesi, C.; Raiteri, E.; Benfenati, F. Kinestics of neuronal and endocrine secretion. J. Endocrinol. Invest., 2004, 27, 128-133.
115. Van Gele, M.; Dynoodt, P.; Lambert, J. Griscelli syndrome: a model system to study vesicular trafficking. Pigment Cell Melanoma Res., 2009, 22, 268-282.
116. Donaldson, J.G.; Williams, D.B. Intracellular assembly and trafficking of MHC class I molecules. Traffic, 2009, 10, 1745-1752.
117. Lanzetti, L.; Fiore, P.P.D. Endocytosis and cancer: an 'insider' network with dangerous liaisons. Traffic, 2008, 9, 2011-2021.
118. Seabra, M.C.; Mules, E.H.; Hume, A.N. Rab GTPases, intracellular traffic and disease. Trends Mol. Med., 2002, 8, 23-30.
119. Wright, P.K. Targeting vesicle trafficking: an importnat approach to cancer chemotherapy. Rec. Pat. Anti-Can. Drug Dis., 2008, 3, 137-147.
120. Ulrich, F.; Heisenberg, C.-P. Trafficking and cell migration. Traffic, 2009, 10, 811-818.
121. Heuser, J. Changes in lysosome shape and distribution correlated with changes in cytoplasmic pH. J. Cell Biol., 1989, 108, 855-864.
122. Glunde, K.; Guggino, S.E.; Solaiyappan, M.; Pathak, A.P.; Ichikawa, Y.; Bhujwalla, Z.M. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia, 2003, 5, 533-545.
123. Palakurthi, S.S.; Aktas, H.; Grubissich, L.M.; Mortensen, R.M.; Halperin, J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor oooand mediated by inhibition of translation initiation. Cancer Res., 2001, 61, 6213-6218.
124. de Dios, S.T.; Hannan, K.M.; Dilley, R.J.; Hill, M.A.; Little, P.J. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J. Diabetes Complications, 2001, 15, 120-127.
125. Blanquicett, C.; Roman, J.; Hart, C.M. Thiazolidinediones as anticancer agents. Cancer Ther., 2008, 6, 25-34.
126. Galli, A.; Ceni, E.; Crabb, D.W.; Mello, T.; Salzano, R.; Grappone, C.; Milani, S.; Surrenti, E.; Surrenti, C.; Casini, A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR{gamma} independent mechanisms. Gut, 2004, 53, 1688-1697.
127. Roman, J. Moving away from PPARs-EGFR signaling and the anti-cancer effects of thiazolinedinediones. Cell Res., 2009, 19, 669-671.
128. Cardone, R.A.; Casavola, V.; Reshkin, S.J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer, 2005, 5, 786-795.
129. + exchange, motility, and invasion induced by serum deprivation. J. Biol. Chem., 2000, 275, 5361-5369.
130. Stock, C.; Schwab, A. Role of the Na/H exchanger NHE1 in cell migration. Acta Physiol. (Oxf), 2006, 187, 149-157.
131. Stock, C.; Schwab, A. Protons make tumor cells move like clockwork. Pflugers Archiv Eur. J. Physiol., 2009, 458, 981-992.
132. Moon, W.S.; Park, H.S.; Lee, H.; Pai, R.; Tarnawski, A.S.; Kim, K.R.; Jang, K.Y. Co-expression of Cox-2, C-Met and B-catenin in cells forming invasive front of gallbladder cancer. Cancer Res. Treat., 2005, 37, 171-176.
133. Sivridis, E.; Giatromanolaki, A.; Koukourakis, M.I. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J. Clin. Pathol., 2005, 58, 1033-1038.
134. Horrée, N.; van Diest, P.J.; Sie-Go, D.M.D.S.; Heintz, A.P.M. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum. Pathol., 2007, 38, 1232-1238.
135. 3-exchangers in migrating renal epithelial cells. J. Gen. Physiol., 2000, 115, 599-608.
136. Tsuji, T.; Ibaragi, S.; Hu, G. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res., 2009, 69, 7135-7139.
137. Acloque, H.; Thiery, J.; Nieto, M. The physiology and pathology of the EMT. EMBO J., 2008, 9, 22-26.
138. Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelialmesenchymal transitions in development and disease. Cell, 2009, 139, 871-890.
139. Thiery, J.P. Metastasis: alone or together? Curr. Biol., 2009, 19, R1121-R1123.
140. Iwatsuki, M.; Mimori, K.; Yokobori, T.; Ishi, H.; Beppu, T.; Nakamori, S.; Baba, H.; Mori, M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci., 2010, 101, 293-299.
141. Desai, B.; Ma, T.; Chellaiah, M.A. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J. Biol. Chem., 2008, 283, 13856-13866.